AU2021227456B2 - Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate - Google Patents

Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate

Info

Publication number
AU2021227456B2
AU2021227456B2 AU2021227456A AU2021227456A AU2021227456B2 AU 2021227456 B2 AU2021227456 B2 AU 2021227456B2 AU 2021227456 A AU2021227456 A AU 2021227456A AU 2021227456 A AU2021227456 A AU 2021227456A AU 2021227456 B2 AU2021227456 B2 AU 2021227456B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
glycopyrrolate
ensifentrine
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021227456A
Other languages
English (en)
Other versions
AU2021227456A1 (en
Inventor
Edward James FRENCH
Phillip Andrew HAYWOOD
Peter Lionel Spargo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verona Pharma Ltd
Original Assignee
Verona Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verona Pharma Ltd filed Critical Verona Pharma Ltd
Publication of AU2021227456A1 publication Critical patent/AU2021227456A1/en
Application granted granted Critical
Publication of AU2021227456B2 publication Critical patent/AU2021227456B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021227456A 2020-02-27 2021-02-26 Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate Active AU2021227456B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2002786.8A GB202002786D0 (en) 2020-02-27 2020-02-27 Liquid pharmaceutical composition
GB2002786.8 2020-02-27
PCT/GB2021/050496 WO2021171034A1 (en) 2020-02-27 2021-02-26 Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate

Publications (2)

Publication Number Publication Date
AU2021227456A1 AU2021227456A1 (en) 2022-09-08
AU2021227456B2 true AU2021227456B2 (en) 2026-07-09

Family

ID=70278709

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021227456A Active AU2021227456B2 (en) 2020-02-27 2021-02-26 Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate

Country Status (25)

Country Link
US (1) US20230112220A1 (cg-RX-API-DMAC7.html)
EP (2) EP4306129A3 (cg-RX-API-DMAC7.html)
JP (2) JP7781762B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220149669A (cg-RX-API-DMAC7.html)
CN (1) CN115279343A (cg-RX-API-DMAC7.html)
AU (1) AU2021227456B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022016015A2 (cg-RX-API-DMAC7.html)
CA (1) CA3166952A1 (cg-RX-API-DMAC7.html)
DK (1) DK4110292T3 (cg-RX-API-DMAC7.html)
ES (1) ES2970571T3 (cg-RX-API-DMAC7.html)
FI (1) FI4110292T3 (cg-RX-API-DMAC7.html)
GB (1) GB202002786D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20240288T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065531T2 (cg-RX-API-DMAC7.html)
IL (1) IL295442A (cg-RX-API-DMAC7.html)
LT (1) LT4110292T (cg-RX-API-DMAC7.html)
MX (1) MX2022010014A (cg-RX-API-DMAC7.html)
PH (1) PH12022552278A1 (cg-RX-API-DMAC7.html)
PL (1) PL4110292T3 (cg-RX-API-DMAC7.html)
PT (1) PT4110292T (cg-RX-API-DMAC7.html)
RS (1) RS65330B1 (cg-RX-API-DMAC7.html)
SI (1) SI4110292T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400076T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021171034A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202208763B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773142T3 (es) 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
EP4609864A4 (en) * 2022-10-28 2026-02-18 Jiangsu Hengrui Pharmaceuticals Co Ltd PHARMACEUTICAL COMPOSITION CONTAINING AN ISOQUINOLINONE COMPOUND AND RELATED PREPARATION PROCESS
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014140648A1 (en) * 2013-03-15 2014-09-18 Verona Pharma Plc Drug combination
WO2016042313A1 (en) * 2014-09-15 2016-03-24 Verona Pharma Plc Liquid inhalation formulation comprising rpl554

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1165558T3 (da) 1999-03-31 2004-02-09 Vernalis Ltd Pyrimido[6,1-a]isoquinolin-4-on-derivater
US20090215734A1 (en) * 2008-02-26 2009-08-27 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014140648A1 (en) * 2013-03-15 2014-09-18 Verona Pharma Plc Drug combination
WO2016042313A1 (en) * 2014-09-15 2016-03-24 Verona Pharma Plc Liquid inhalation formulation comprising rpl554

Also Published As

Publication number Publication date
FI4110292T3 (fi) 2024-03-01
US20230112220A1 (en) 2023-04-13
SMT202400076T1 (it) 2024-03-13
PL4110292T3 (pl) 2024-05-20
JP2026035711A (ja) 2026-03-04
SI4110292T1 (sl) 2024-03-29
IL295442A (en) 2022-10-01
MX2022010014A (es) 2022-10-18
JP7781762B2 (ja) 2025-12-08
DK4110292T3 (da) 2024-02-19
ZA202208763B (en) 2024-01-31
KR20220149669A (ko) 2022-11-08
RS65330B1 (sr) 2024-04-30
LT4110292T (lt) 2024-02-12
PT4110292T (pt) 2024-01-31
EP4306129A2 (en) 2024-01-17
EP4110292A1 (en) 2023-01-04
ES2970571T3 (es) 2024-05-29
HRP20240288T1 (hr) 2024-05-24
HUE065531T2 (hu) 2024-05-28
JP2023516630A (ja) 2023-04-20
CN115279343A (zh) 2022-11-01
GB202002786D0 (en) 2020-04-15
EP4110292B1 (en) 2024-01-10
BR112022016015A2 (pt) 2022-10-11
EP4306129A3 (en) 2024-04-17
AU2021227456A1 (en) 2022-09-08
WO2021171034A1 (en) 2021-09-02
CA3166952A1 (en) 2021-09-02
PH12022552278A1 (en) 2024-03-04